Evidence map›Paper›PMID 37466793›Full record

ArticleJournal of cancer research and clinical oncology2023

Establishment of a prognostic model based on m

Yan Liang, Sen Chen, Jinghe Xie, Guanrong Yan, Tingting Guo, Tianyang Li, Shoupei Liu, Weiping Zeng, Shuai Zhang, Keqiang Ma and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. mFrontiers in immunology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yan Liang *Laboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Sen Chen *Laboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Jinghe Xie *School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Guanrong YanSchool of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Tingting GuoLaboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Tianyang LiDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, No.1 Panfu Road, Guangzhou, 510180, People's Republic of China.
Shoupei LiuLaboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Weiping ZengLaboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Shuai ZhangDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, No.1 Panfu Road, Guangzhou, 510180, People's Republic of China.
Keqiang MaDepartment of Hepatobiliary Pancreatic Surgery, Huadu District People's Hospital of Guangzhou, Guangzhou, 510800, People's Republic of China.
Honglin ChenLaboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Yimeng OuDepartment of General Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, 19 Nonglin Xia Road, Guangzhou, 510699, People's Republic of China. yimengou@126.com.
Bailin WangDepartment of General Surgery, Guangzhou Red Cross Hospital, Jinan University, 601 Huangpu Dadao West Road, Guangzhou, 510220, People's Republic of China. wangbailin888@sina.com.
Weili GuDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, No.1 Panfu Road, Guangzhou, 510180, People's Republic of China. lili-6423@163.com.
Yuyou DuanLaboratory of Stem Cells and Translational Medicine, School of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China. yuyouduan@scut.edu.cn.

Funding

GuangZhou Basic and Applied Basic Research Foundation 202201010538Key Project of Guangzhou Science and Technology Program No. 202102010027Research Agreement between South China University of Technology and Guangzhou First People's Hospital D9194290Research Starting Funding of South China University of Technology D6181910Research Starting Funding of South China University of Technology D6201880Research Starting Funding of South China University of Technology K5180910Research Starting Funding of South China University of Technology K5204120Research Starting Funding of the Second affiliated Hospital of South China University of Technology KY09060026
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) with high incidence and mortality is one of the most common malignant cancers worldwide. Increasing evidence has reported that N6-methyladenosine (m

methodIn our study, we comprehensively analyzed the connection between m

resultsFour regulatory factors RBM15B, LRPPRC, IGF2BP1, and IGF2BP3 were picked as valuable prognostic indicators.

conclusionIn summary, these ten hub regulatory factors would be useful therapeutic targets for HCC treatment, and RBM15B/LRPPRC/IGF2BP1/IGF2BP3 prognostic indicators can be used to guide therapy for HCC patients.

Indexed as

AdenosineBiomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsNeoplastic Stem CellsGene Expression Regulation, NeoplasticHumansPrognosisRNA-Binding ProteinsRNA-SeqSingle-Cell Gene Expression AnalysisAdenosineBiomarkers, TumorN-methyladenosineRNA-Binding ProteinsCSCsHCCm6A modificationPrognostic modelStemness

Identifiers

PMID37466793
PMCPMC10587019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.